The U.S. Food and Drug Administration (FDA) today announced it amended the emergency use authorizations of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals.
This action on April 18, 2023, includes authorizing the current bivalent vaccines (original and omicron BA.4/BA.5 strains) for all doses administered to individuals six months of age and older, including for an additional dose or doses for specific populations.
COVID-19 mRNA Booster Authorizations Expanded
SARS-CoV-2 Infection Linked to Increased Risk for Diabetes
Fraction of incident diabetes cases attributable to SARS-CoV-2 infection was 3.41 percent overall, 4.75 percent among men
Oral Fluvoxamine Plus Budesonide Cuts Severe Disease in COVID-19
Reduction in incidence of severe disease requiring advanced care seen among high-risk outpatients with COVID-19
FDA Authorizes Spring COVID-19 Booster for Certain Americans
Original mRNA vaccines are being pulled from the market in favor of the bivalent vaccines, which target both the omicron variant and the original strain of COVID-19